Excess of second tumors in denosumab-treated patients: a metabolic hypothesis

Future Oncol. 2019 Jul;15(20):2319-2321. doi: 10.2217/fon-2019-0170. Epub 2019 Jun 25.

Authors

Valeria Tovazzi¹, Alberto Dalla Volta², Rebecca Pedersini¹, Vito Amoroso¹, Alfredo Berruti¹

Affiliations

¹ Department of Medical & Surgical Specialties, Radiological Sciences, & Public Health, Medical Oncology, University of Brescia at ASST Spedali Civili, Brescia, Italy.
² ASST Spedali Civili of Brescia Medical Oncology, University of Verona, Verona, Italy.

PMID: 31237145
DOI: 10.2217/fon-2019-0170

No abstract available

Keywords: denosumab; hyperparathyroidism; hypocalcemia; second malignancies.

MeSH terms

Bone Density Conservation Agents / administration & dosage
Bone Density Conservation Agents / adverse effects*
Bone Neoplasms / drug therapy
Bone Neoplasms / secondary
Denosumab / administration & dosage
Denosumab / adverse effects*
Humans
Hypocalcemia / chemically induced
Hypocalcemia / complications
Neoplasms / drug therapy*
Neoplasms, Second Primary / chemically induced*
Parathyroid Hormone / blood
RANK Ligand / antagonists & inhibitors
RANK Ligand / metabolism

Substances

Bone Density Conservation Agents
Parathyroid Hormone
RANK Ligand
TNFSF11 protein, human
Denosumab